Lung cancer patients share why they quit lifesaving pill
NCT ID NCT07542210
First seen Apr 22, 2026 · Last updated Jun 13, 2026 · Updated 10 times
Summary
This study talks to about 85 lung cancer patients and 15 doctors in China to find out what makes it hard or easy to keep taking the drug osimertinib after surgery. The goal is to learn about side effects, costs, support, and communication issues so that future patients can stay on treatment longer. No new drugs are tested—just interviews to gather insights.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
Beijing, China
Conditions
Explore the condition pages connected to this study.